Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Candel Therapeutics Inc (CADL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CADL (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 116.47% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 134.29M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1340867 | Beta -0.87 | 52 Weeks Range 2.00 - 14.30 | Updated Date 03/30/2025 |
52 Weeks Range 2.00 - 14.30 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date 2025-03-14 | When - | Estimate - | Actual -0.3957 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.31% | Return on Equity (TTM) -480.68% |
Valuation
Trailing PE - | Forward PE 43.48 | Enterprise Value 173918512 | Price to Sales(TTM) 436.42 |
Enterprise Value 173918512 | Price to Sales(TTM) 436.42 | ||
Enterprise Value to Revenue 821.98 | Enterprise Value to EBITDA -0.01 | Shares Outstanding 32475500 | Shares Floating 21676796 |
Shares Outstanding 32475500 | Shares Floating 21676796 | ||
Percent Insiders 30.39 | Percent Institutions 22.53 |
Analyst Ratings
Rating 4 | Target Price 11 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Candel Therapeutics Inc
Company Overview
History and Background
Candel Therapeutics, Inc. is a late clinical stage biopharmaceutical company focused on developing oncolytic viral immunotherapies to help patients fight cancer. Founded in 2003, Candel is pioneering a new class of immune-oncologic medicines based on systemically delivered oncolytic viral immunotherapies to treat solid tumors.
Core Business Areas
- Oncolytic Viral Immunotherapies: Developing and commercializing oncolytic viral immunotherapies for the treatment of cancer. The company focuses on engineering viruses to selectively infect and kill cancer cells while stimulating an immune response.
Leadership and Structure
Dr. Paul Peter Tak is the CEO. The company has a board of directors and a management team focused on clinical development, research, and business operations.
Top Products and Market Share
Key Offerings
- CAN-2409: CAN-2409 is an off-the-shelf adenovirus product being developed for non-small cell lung cancer, pancreatic cancer, and other solid tumors. It is designed to induce a targeted immune response against the tumor. Competitors are other immunotherapy approaches, including checkpoint inhibitors and other oncolytic viruses under development.
- CAN-3110: CAN-3110 is an oncolytic herpes simplex virus being developed for glioma. It is designed to selectively infect and kill cancer cells in the brain. Competitors include surgery, radiation therapy, chemotherapy, and other targeted therapies.
Market Dynamics
Industry Overview
The oncology market is characterized by significant unmet needs and intense competition. Immunotherapy is a rapidly growing segment, with increasing focus on personalized and combination therapies.
Positioning
Candel Therapeutics is positioned as a company developing novel oncolytic viral immunotherapies, targeting solid tumors with unmet needs. The companyu2019s systemic delivery approach differentiates it from some competitors.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is estimated to be in the tens of billions of dollars annually. Candel is targeting specific solid tumor types within this broader market.
Upturn SWOT Analysis
Strengths
- Novel technology platform
- Systemic delivery of oncolytic viruses
- Strong intellectual property portfolio
- Experienced management team
- Clinical trial progress
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- High cash burn rate
- Need for additional financing
- Concentrated product pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new indications
- Positive clinical trial results
- Advancements in immunotherapy
- Increased adoption of oncolytic viruses
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent challenges
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- AMGN
- BMY
- MRK
Competitive Landscape
Candel Therapeutics competes with larger pharmaceutical companies developing cancer immunotherapies. Candel's systemic delivery approach for oncolytic viruses offers a potential advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to clinical trial progress and potential partnerships. Historical data is needed for more specifics.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates vary and can be found on financial websites.
Recent Initiatives: Recent initiatives include advancing clinical trials for CAN-2409 and CAN-3110, and seeking partnerships to expand reach.
Summary
Candel Therapeutics is a clinical-stage biopharmaceutical company pioneering oncolytic viral immunotherapies. Its strengths lie in its innovative technology and experienced team, but it faces challenges related to clinical trial success and financial stability. Its future depends on successful clinical development, partnerships, and effective commercialization strategies. The company must carefully manage its resources and navigate the competitive landscape to achieve its goals.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Candel Therapeutics' Investor Relations Website
- SEC Filings (10-K, 10-Q)
- Company Press Releases
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Candel Therapeutics Inc
Exchange NASDAQ | Headquaters Needham, MA, United States | ||
IPO Launch date 2021-07-27 | President, CEO & Director Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.candeltx.com |
Full time employees 38 | Website https://www.candeltx.com | ||
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.